{
  "abstract": "Background Pulmonary Hypertension associated with Lung Disease and/or Hypoxia (PH-LD), including PH with interstitial lung disease (PH-ILD), are severe conditions with a high mortality. However, data on epidemiology and healthcare management in the real-world setting are limited.Objective To estimate the epidemiology and the healthcare resource use (HCRU) of patients with PH-LD/ILD.Methods We conducted a retrospective observational study using the UK Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES), including >18 million patients. An algorithm, developed with six PH medical experts, identified PH-LD and PH-ILD patients from January 2017 to December 2019 based on a combination of PH and LD ICD-10 codes. The index date was the first PH diagnosis, with a 24-month minimum lookback period and up to 60 months follow-up until end of study, loss to follow-up or death.Results A total of 6,690 patients with PH-LD (mean age 71, 54% female) and 1,561 with PH-ILD (mean age 71, 62% female) were included. The estimated period prevalence (2017–2019) and annual incidence of PH-LD was 2.65 (95%CI 2.59–2.70) and 0.67 (0.651–0.68) per 10,000 people, and PH-ILD 0.66 (95%CI 0.64–0.69) and 0.16 (0.15–0.16), respectively. During the first-year of follow-up, incident PH-LD and PH-ILD patients had a mean (95%CI) 3.46 (3.40–3.51) and 2.93 (2.82–3.03) all-cause inpatient hospitalizations per person-year, including 1.87 (1.83–1.91) and 1.78 (1.70–1.87) due to PH, and 2.94 (2.89–2.99) and 2.51 (2.41–2.60) due to LD. Mean length of stay (SD) was 10 (15) and 10 (13) days, respectively. Hospitalization rates decreased over time. One, two, and three-year survival rates (95%CI) for PH-LD and PH-ILD patients were 58% (57%-59%), 46% (45%-48%), and 40% (39%-41%), and 53% (51%-56%), 43% (41%-46%), and 38% (35%-40%), respectively.Conclusion With current therapies patients with PH-LD and PH-ILD have a significant unmet need with high levels of HCRU and a poor prognosis.",
  "authors": [
    {
      "affiliations": [
        "NIHR Biomedical Research Centre, London, UK",
        "Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"
      ],
      "name": "D Kiely"
    },
    {
      "affiliations": [
        "Royal Brompton Hospital and Imperial College, London, UK"
      ],
      "name": "SJ Wort"
    },
    {
      "affiliations": [
        "Ferrer Internacional, Barcelona, Spain"
      ],
      "name": "D Funes"
    },
    {
      "affiliations": [
        "Alira Health, Paris, France"
      ],
      "name": "N Petrica"
    },
    {
      "affiliations": [
        "Alira Health, Basel, Switzerland"
      ],
      "name": "C Proenca"
    },
    {
      "affiliations": [
        "Alira Health, Paris, France"
      ],
      "name": "M Pini"
    },
    {
      "affiliations": [
        "Ferrer Internacional, Barcelona, Spain"
      ],
      "name": "M Fernández Delgado"
    },
    {
      "affiliations": [
        "Ferrer Internacional, Barcelona, Spain"
      ],
      "name": "G Bacchini Jeanneret"
    }
  ],
  "title": "S81 Epidemiology, prognosis, and healthcare resource use of patients with pulmonary hypertension associated with lung disease and/or hypoxia in the UK",
  "uid": "4d3b1842-a265-534c-8b15-fce542009ad9"
}